How Did AVITA Medical Inc. (ASX:AVH) Narrow Its First-Half Loss While Increasing Revenue?

Aditi Sarkar

04 November 2026 11:44 PM AEDT

How Did AVITA Medical Inc. (ASX:AVH) Narrow Its First-Half Loss While Increasing Revenue?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

AVITA Medical Inc. (ASX:AVH) reported first-half 2026 Revenue of USD 41.0 million, up 11% from USD 36.9 million.
Net loss narrowed 23% to USD 18.3 million, compared with USD 23.8 million in the prior corresponding half.
Other income decreased to approximately USD 0.3 million from USD 1.7 million.
Net Tangible Asset backing declined to negative USD 1.1558 per ordinary share at June 2026.
The company identified stronger RECELL utilisation, new-product growth and debt-refinancing effects in its half-year report.

AVITA Medical Inc. (ASX:AVH) develops wound-care technologies, including products used in treating burns and other skin injuries. Its results announcement for the six months ended 30 June 2026 reported higher revenue and a smaller net loss than the comparative half-year. The filing also described improved use of RECELL and contributions from newer products. However, the Balance Sheet remained in a negative net tangible asset position, and the company identified additional liabilities associated with refinancing activity.

First-Half Revenue and Loss Comparison

AVH reported revenue of USD 40.953 million for the half-year ended June 2026, up from USD 36.932 million in the corresponding 2025 period. The increase was approximately 11%, based on the company’s results announcement. The growth was attributed in the filing to greater RECELL utilisation and newer-product activity rather than a single disclosed product revenue line.

The net loss decreased to USD 18.274 million from USD 23.779 million, representing a 23% reduction. The improvement is relevant to operating progress but does not indicate that the company had reached profitability. Other income also declined, from USD 1.693 million to USD 0.293 million, affecting the wider comparison between the two periods.

Product Use and Commercial Execution

In the half-year release, AVH highlighted improved RECELL utilisation and growth from new products. RECELL is associated with the company’s treatment technologies for wound care, where Demand depends on clinical use, procedure activity and healthcare purchasing arrangements. The short release did not provide a detailed numerical breakdown of performance by product.

For that reason, the reported total revenue increase should not be assigned to an individual product category beyond the company’s own general commentary. Expansion of clinical use may support further activity, but the scale of future revenue will depend on customer adoption, ordering patterns and sales execution in the healthcare channels served by AVH.

Net Tangible Assets and Borrowings

AVH reported net tangible assets of negative USD 35.744 million at June 2026, compared with negative USD 21.288 million in June 2025. Net tangible asset backing per ordinary share was negative USD 1.1558, against negative USD 0.7999 in the prior period.

The filing noted increased liabilities associated with Debt refinancing to support growth. It also reported an increase in ordinary shares on issue from 26.614 million to 30.927 million. These measures relate to financing and the balance sheet, and are distinct from the operational progress reflected in reported revenue.

Cash Flow Objectives and Disclosure Limits

Management linked the reduction in first-half losses to revenue growth and cost-control measures. The company described an objective of Cash Flow break-even in 2026 and profitability in 2027. These objectives represent management expectations and are not evidence that either financial milestone had already been achieved.

The supplied Appendix 4E summary does not contain the complete Operating Cash Flow detail or all the segment information required to independently evaluate those goals. Subsequent financial statements and company updates would be needed to assess liquidity, changes in Working Capital and progress toward the stated objectives. The half-year figures remain the basis for this article.

Key Insights

AVH reported an 11% increase in first-half 2026 revenue and a 23% reduction in net loss, supported by the operating developments described in its release. At the same time, net tangible asset backing remained negative and liabilities increased in connection with refinancing.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.